HCA Healthcare, Inc.
$138.89B- Market cap
- $93.44B
- Debt
- +$46.49B
- Cash
- −$1.04B
Capital structure 67% equity / 33% debt · EV / Revenue 1.84x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: HCA stock price at discount vs WMT $421.21 current versus $1.10K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WMT's multiple
Implied fair value · at HCA's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple premium
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 67% equity / 33% debt · EV / Revenue 1.84x
Capital structure 95% equity / 5% debt · EV / Revenue 1.22x
WMT carries the larger enterprise value at $872.87B against $138.89B; WMT trades on the lower EV / Revenue multiple (1.22x vs 1.84x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$171.11
Base
$241.68
Bull
$336.89
WALMART INC. · implied price per share
Bear
$26.01
Base
$31.42
Bull
$38.87
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
TARGET CORP
HCA vs TGT
Costco Wholesale Corporation
HCA vs COST
Amazon.com, Inc.
HCA vs AMZN
CVS Health Corporation
HCA vs CVS
Walgreens Boots Alliance, Inc.
HCA vs WBA
DOLLAR GENERAL CORP
HCA vs DG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA’s higher margin profile and faster revenue growth deserve a valuation closer to WMT’s earnings multiple, then owning HCA makes sense because its current P/E of 14.2x is far below WMT’s 40.8x; if you think WMT comparison is too aggressive, the current price already sits within the historical band and below the DCF range, which argues for patience rather than chasing the implied upside.
HCA screens at a much lower P/E and EV/EBITDA than WMT, implying a large valuation discount on earnings power. However, WMT-implied upside of 187.2% is far above both the historical band and the DCF range, suggesting the market is not willing to underwrite WMT multiple as a direct comp.
Supporting Metrics